Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 706 to 720 of 1094 results for infections

  1. How many people in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?

    Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43 Date issued December 2012 Other

    Research recommendation
    Published
    9 June 2015

  2. What cost-effective interventions can be used to increase hepatitis B case-finding among migrant populations in primary and secondary care?

    Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43 Date issued December 2012 Other

    Research recommendation
    Published
    9 June 2015

  3. How cost effective are alternative testing sites, such as community pharmacist programmes, for increasing the number of people who are tested and treated for hepatitis B and C?

    Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43 Date issued December 2012 Other

    Research recommendation
    Published
    9 June 2015

  4. What impact does increased knowledge and awareness of hepatitis B and C among the general public have on the uptake of testing and treatment?

    Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43 Date issued December 2012 Other

    Research recommendation
    Published
    9 June 2015

  5. Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain (HTG399)

    Evidence-based recommendations on percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain. This involves relieving low back pain by delivering heat energy to the damaged disc.

    HealthTech guidance
    Published
    27 January 2016
    View recommendations

    Sections for HTG399

  6. Curos for preventing infections when using needleless connectors (MTG44)

    We have moved Medical technologies guidance 44 to become HealthTech guidance 510. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  7. How can the uptake of hepatitis C treatment be improved? What factors influence whether or not specific groups at increased risk will begin and complete hepatitis C treatment?

    Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43 Date issued December 2012 Other

    Research recommendation
    Published
    9 June 2015

  8. Research should report:

    including: bleeding symptomatic and asymptomatic intracranial bleeding infection cannulation complications pain. Source guidance details

    Research recommendation
    Published
    11 January 2024

  9. Intrapartum antibiotics: What is the clinical and cost effectiveness of intrapartum antibiotics for women with meconium-stained amniotic fluid?

    Source guidance details Comes from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195

    Research recommendation
    Published
    6 August 2021

  10. Hand decontamination:- When clean running water is not available, what is the clinical and cost effectiveness of using wipes, gels, handrubs or other products to remove visible contamination?

    guidance details Comes from guidance Healthcare-associated infections: prevention and control in primary and community care Number

    Research recommendation
    Published
    9 June 2015

  11. Blood transfusion (NG24)

    This guideline covers the assessment for and management of blood transfusions in adults, young people and children over 1 year old. It covers the general principles of blood transfusion, but does not make recommendations relating to specific conditions.

    NICE guideline
    Published
    18 November 2015
    View recommendations

    Sections for NG24

  12. Faecal microbiota transplant for recurrent Clostridioides difficile infection (MTG71)

    We have moved Medical technologies guidance 71 to become HealthTech guidance 638. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  13. Faecal microbiota transplant for recurrent Clostridium difficile infection (IPG485)

    We have moved interventional procedures guidance 485 to become HealthTech guidance 338. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  14. Acute hepatic encephalopathy:- In people with cirrhosis and an acute episode of hepatic encephalopathy secondary to a clearly identified, potentially reversible precipitating factor, does management of the precipitating event alone improve the hepatic encephalopathy without specific treatment?

    encephalopathy there is a clearly defined precipitating factor (for example, infections, gastrointestinal bleeding or overuse of...

    Research recommendation
    Published
    11 January 2024

  15. Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)

    Evidence-based recommendations on rituximab for untreated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    22 July 2009
    View recommendations

    Sections for TA174